SavedAdd your journal

Journals / Androloji Bülteni / 2020 / Cilt: 22 - Sayı: 4

Important points of usage of alpha-1 receptor blocker drugs in the treatment of BPH and new areas of clinical usage

Alfa -1 reseptör blokeri ilaçların benign prostat hiperplazisi tedavisindeki kullanımlarının önemli noktaları ve yeni klinik kullanım alanları

Ali ATAN
Pages
238–243
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In all areas of clinical usage, the choice of alpha-1 receptor blockers should be made considering the side effects on the cardiovascular system and sexual functions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the urology practice, alpha-1 receptor blocker drugs have been for the treatment of LUTS associated with BPH for about fifty years.
📊
Key Findings & Data:The commonly used alpha-1 receptor blocker drugs are alfuzosin, doxazosin, terazosin, tamsulosin and silodosin.
💡
Conclusion & Impact:In all areas of clinical usage, the choice of alpha-1 receptor blockers should be made considering the side effects on the cardiovascular system and sexual functions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In the urology practice, alpha-1 receptor blocker drugs have been for the treatment of LUTS associated with BPH for about fifty years. The commonly used alpha-1 receptor blocker drugs are alfuzosin, doxazosin, terazosin, tamsulosin and silodosin. These drugs are considered as first-line therapy for the treatment of LUTS associated with BPH. All alpha-1 receptor blockers have similar efficacy and there was no significant difference in terms of the efficacy among them. With alpha-1 receptor blocker drugs, a 20–40% increase in urine flow rate and a 30– 50% decrease in symptoms were achieved. In recent years, new areas of clinical usage of alpha-1 receptor blocker drugs have been developed. These new areas of the clinical usage are acute urinary retention and urinary tract stone disease. In all areas of clinical usage, the choice of alpha-1 receptor blockers should be made considering the side effects on the cardiovascular system and sexual functions.

Özet

Alfa-1 reseptör blokeri ilaçlar elli yıla yakın bir süredir BPH ile ilişkili AÜSY tedavisinde üroloji pratiği içerisindedir. Yaygın olarak kullanılan alfa-1 reseptör blokeri ilaçlar alfuzosin, doksazosin, terazosin, tamsulosin ve silodosindir. Bu ilaçlar BPH ile ilişkili AÜSY tedavisinde ilk basamak tedavi olarak kabul edilmektedir. Tüm alfa-1 reseptör blokerler benzer etkinliktedir ve aralarında etkinlik açısından belirgin bir fark bulunmamıştır. Alfa-1 reseptör blokeri ilaçlar ile idrar akım hızında %20–40 düzeyinde bir artış ve semptomlarda %30–50 düzeyinde bir azalma sağlanmıştır. Son yıllarda alfa-1 reseptör blokeri ilaçların yeni klinik kullanım alanları geliştirilmiştir. Bu yeni klinik kullanım alanları akut üriner retansiyon ve üriner sistem taş hastalığıdır. Tüm klinik kullanım alanlarında, alfa-1 reseptör bloker seçimi kardiyovasküler sistem ve cinsel fonksiyonlar üzerindeki yan etkileri dikkate alınarak yapılmalıdır

🔖

Cite This Article

ATAN, A. (2020). Important points of usage of alpha-1 receptor blocker drugs in the treatment of BPH and new areas of clinical usage. Androloji Bülteni, Cilt: 22 - Sayı: 4, 238–243. https://ajindex.com/articles/142457

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. BJU 1975
  2. 193– 202. [CrossRef] 2. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979
  3. 487–9. [CrossRef] 3. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004
  4. 1029–35. [CrossRef] 4. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011
  5. 876–80. [CrossRef] 5. Gül ZG, Kaplan SA. BPH. Why Do Patients Fail Medical Therapy? Curr Urol Rep 2019
  6. [CrossRef] 6. Gravas S, Cornu JN, Gacci MC, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of Non-neurogenic Male LUTS, 2020. https:// uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ 7. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–803. [CrossRef] 8. Roehrborn CG and Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebocontrolled studies. Urology 1996
  7. 404–15. [CrossRef] 9. Samli MM and Dincel C. Terazosin and doxazosin in the treatment of BPH. results of a randomized study with crossover in non-responders. Urol Int 2004
  8. 125–9. [CrossRef] 10. Senkul T, Yilmaz O, Iseri C, Adayener C, Akyol I, Ates F. Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. Int Urol Nephrol 2008
  9. 663–6. [CrossRef] 11. Karadağ E, Öner S, Budak YU, Atahan Ö. Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. Int Urol Nephrol 2011
  10. 949–54. [CrossRef] 12. Atan A, Başar MM, Yıldız M, Akalın Z. The effect of age in the usage of alpha receptor blocker treatment in prostate patients. Arch Ital Urol Androl 1997
  11. 299–301. https://pubmed.ncbi.nlm.nih.gov/9477614/ 13. Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998
  12. 332–5. [CrossRef] 14. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of low